The American Society for Pharmacology and Experimental Therapeutics (ASPET) is a 4,000 member scientific society whose members conduct basic and clinical pharmacological research and work for academia, government, large pharmaceutical companies, small biotech companies, and non-profit organizations.
ASPET members work in a variety of different fields and include neuroscientists, toxicologists, chemical biologists, pharmacists, cardiovascular scientists, and many more. Though very diverse, our members have a common bond through their membership in ASPET. Our members' research efforts help develop new medicines and therapeutic agents to fight existing and emerging diseases.
Pharmacology is an essential integrative discipline that creates new knowledge about drug action and translates those discoveries into novel therapeutics. In order to improve health and cure disease, ASPET will be an advocate for everyone practicing this discipline.
To be the professional home for educators, students, researchers, healthcare practitioners, and other professionals working to advance pharmacology research, exchange knowledge, and increase the impact and influence of this scientific discipline.
ASPET’s strategic plan highlights the approaches that the ASPET Council sees as necessary to keep pharmacology at the cutting edge of biomedical research and education. Read the 2017 ASPET Strategic Plan.
ASPET is governed by an elected council consisting of a president, past president, president-elect, secretary/treasurer, past secretary/treasurer, secretary/treasurer-elect, and three councilors. The chair of the Board of Publications Trustees, the chair
of the Program Committee, the ASPET representative to the FASEB Board and the executive officer serve as non-voting ex officio members of the council.
ASPET supports ten divisions, each of which is governed by an executive committee.